Edwards Lifesciences Corp (EW) — SEC Filings
Edwards Lifesciences Corp (EW) — 34 SEC filings. Latest: 8-K (May 8, 2026). Includes 20 8-K, 6 10-Q, 3 SC 13G/A.
View Edwards Lifesciences Corp on SEC EDGAR
Overview
Edwards Lifesciences Corp (EW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Edwards Lifesciences Corp (EW) reported net sales of $1,553.1 million for the three months ended September 30, 2025, an increase from $1,354.4 million in the prior year period. However, net income attributable to Edwards Lifesciences Corporation significantly decreased to $291.1 million for the quar
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 31 neutral, 2 mixed. The dominant filing sentiment for Edwards Lifesciences Corp is neutral.
Filing Type Overview
Edwards Lifesciences Corp (EW) has filed 20 8-K, 6 10-Q, 1 DEFA14A, 1 DEF 14A, 2 10-K, 1 SC 13G, 3 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of EW's 27 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,553.1M |
| Net Income | $291.1M |
| Cash Position | $2,685.6M |
| Total Assets | $13,272.2M |
| Total Debt | $598.2M |
Key Executives
- Michael Mussallem
- Bernard Zovighian
- David E. Wood
- Robert H. Daily, Jr.
- Sarah E. Glickman
- David E.I. Pyott
- Sarah K. St. James
- Scott Ullem
- Brian W. Fox
Industry Context
Edwards Lifesciences operates in the highly specialized medical device industry, focusing on structural heart disease and critical care monitoring. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA, etc.), and a competitive landscape with established players and emerging innovators. Trends include the shift towards minimally invasive procedures, technological advancements in device design, and increasing demand driven by an aging global population.
Top Tags
financial-reporting (7) · 8-K (5) · 8-k (5) · Medical Devices (4) · corporate-governance (4) · sec-filing (4) · 10-Q (4) · medical-devices (4) · financials (3) · cfo-appointment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net sales (Q3 2025) | $1,553.1M | Increased from $1,354.4M in Q3 2024 |
| Net income attributable to EW (Q3 2025) | $291.1M | Decreased significantly from $3,070.8M in Q3 2024 due to prior year's asset sale |
| Certain litigation expenses (Q3 2025) | $90.4M | Increased from $10.8M in Q3 2024 |
| Intangible assets impairment charges (Q3 2025) | $40.0M | New charge, zero in Q3 2024 |
| Purchases of treasury stock (9 months ended Sep 30, 2025) | $852.8M | Contributed to decrease in cash and cash equivalents |
| Purchase of remaining noncontrolling interest (9 months ended Sep 30, 2025) | $233.7M | Eliminated noncontrolling interest |
| Cash and cash equivalents (Sep 30, 2025) | $2,685.6M | Decreased from $3,045.2M at Dec 31, 2024 |
| Selling, general, and administrative expenses (Q3 2025) | $514.6M | Increased from $421.4M in Q3 2024 |
| Q2 2025 Net Sales | $1.60B | Up 9% from Q2 2024's $1.47B, indicating strong growth. |
| Q2 2025 Net Income | $420M | Increased 10.5% from Q2 2024's $380M, showing improved profitability. |
| H1 2025 Net Sales | $3.15B | Grew 8.6% from H1 2024's $2.90B, reflecting sustained performance. |
| H1 2025 Net Income | $810M | Rose 9.5% from H1 2024's $740M, demonstrating consistent profit expansion. |
| H1 2025 Cash Flow from Operations | $950M | Strong cash generation supports investment and financial health. |
| H1 2025 R&D Expenses | $300M | Increased from $280M in H1 2024, showing continued investment in innovation. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter covered by the report. |
Forward-Looking Statements
- {"claim":"Edwards Lifesciences will continue to operate under the same SIC code [3842] for the foreseeable future.","entity":"Edwards Lifesciences Corp.","targetDate":"2025-12-31","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Edwards Lifesciences Corp (EW)?
Edwards Lifesciences Corp has 34 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EW filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 31 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Edwards Lifesciences Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Edwards Lifesciences Corp (EW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Edwards Lifesciences Corp?
Key financial highlights from Edwards Lifesciences Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EW?
The investment thesis for EW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Edwards Lifesciences Corp?
Key executives identified across Edwards Lifesciences Corp's filings include Michael Mussallem, Bernard Zovighian, David E. Wood, Robert H. Daily, Jr., Sarah E. Glickman and 4 others.
What are the main risk factors for Edwards Lifesciences Corp stock?
Of EW's 27 assessed filings, 0 were flagged high-risk, 8 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Edwards Lifesciences Corp?
Recent forward-looking statements from Edwards Lifesciences Corp include guidance on {"claim":"Edwards Lifesciences will continue to operate under the same SIC code [3842] for the foreseeable future.","ent.